Drug Combination Details
| General Information of the Combination (ID: C23550) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | Depsipeptide Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Lung cancer
[ICD-11: 2C25]
|
Phase 1 | [1] | ||
|
Pleural mesothelioma
[ICD-11: 2C26]
|
Phase 1 | [1] | |||
|
Oral cavity/oesophagus/stomach in situ carcinoma
[ICD-11: 2E60]
|
Phase 1 | [1] | |||
|
Thymoma
[ICD-11: 2C27]
|
Phase 1 | [1] | |||
|
Mediastinum cancer
[ICD-11: 2C28]
|
Phase 1 | [1] | |||
|
Esophageal cancer
[ICD-11: 2B70]
|
Investigative | [2] | |||
| Click to Show/Hide the Whole Disease Information of This Combination | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [3] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | c-RAF | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | CCNA1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | EGFR | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Expression | HER2 | Molecule Info |
Pathway MAP
|
||
| Down-regulation | Phosphorylation | RB1 | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | NCI-H513 | CVCL_A570 | Malignant pleural mesothelioma | Homo sapiens | ||
| NCI-H28 | CVCL_1555 | Pleural sarcomatoid mesothelioma | Homo sapiens | |||
| NCI-H2373 | CVCL_A533 | Pleural sarcomatoid mesothelioma | Homo sapiens | |||
| NCI-H2052 | CVCL_1518 | Pleural sarcomatoid mesothelioma | Homo sapiens | |||
| REN | CVCL_M202 | Pleural malignant mesothelioma | Homo sapiens | |||
| Experimental
Result(s) |
Flavopiridol abrogates depsipeptide-mediated induction of p21 expression, in part, via inhibition of protein kinase C signaling and markedly potentiates the cytotoxic effects of depsipeptide in MPM cells. | |||||
| Experiment 2 Reporting the Effect of This Combination | [2] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP9 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Induction | Loss of mitochondrial membrane potential | ||||
| In-vitro Model | NCI-H322 | CVCL_1556 | Lung adenocarcinoma | Homo sapiens | ||
| NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | |||
| TE-12 | CVCL_1762 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| TE-13 | CVCL_4463 | Esophageal squamous cell carcinoma | Homo sapiens | |||
| Experimental
Result(s) |
The depsipeptide plus flavopiridol combination exhibits powerful and selective cytocidal activity against cancer but not normal cells. Apoptosis induced by this combination is mediated by the mitochondria-dependent death pathway. | |||||
